LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Stock List・Prothena Corp PLC

Prothena Corp PLC

Closed

SectorHealthcare

10.31 -4.09

Buy Sell

Overview

Share price change

24h

Current

Min

10.19

Max

10.75

Key metrics
By Trading Economics
Income	89M -37M
Sales	-2M 2.4M
Profit margin	-1,513.085
Employees	163
EBITDA	16M -36M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+93.85% upside

Market Stats
By TradingEconomics
Market Cap	10M 578M
Previous open	14.4
Previous close	10.31

News Sentiment

By Acuity

42%

58%

156 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

N/A / 7.35 Support & Resistance

Prothena Corp PLC Chart

Past performance is not a reliable indicator of future results.

Related News

9 Dec 2025, 22:13 UTC

Earnings

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

9 Dec 2025, 21:40 UTC

Earnings

GameStop Sales Fall as Collectibles Remain Only Bright Spot

9 Dec 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

9 Dec 2025, 16:57 UTC

Major Market Movers

Clear Secure Rises on Medicare Identity Verification Contract

9 Dec 2025, 23:46 UTC

Market Talk

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

9 Dec 2025, 23:46 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings Stake in Lenovo Now at 32.34%

9 Dec 2025, 23:45 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

9 Dec 2025, 23:44 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

9 Dec 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

9 Dec 2025, 23:43 UTC

Acquisitions, Mergers, Takeovers

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

9 Dec 2025, 23:35 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

9 Dec 2025, 22:42 UTC

Earnings

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

9 Dec 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

9 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Dec 2025, 21:48 UTC

Market Talk

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

9 Dec 2025, 21:36 UTC

Earnings

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

9 Dec 2025, 20:28 UTC

Market Talk

Oil Futures Decline for Second Straight Session -- Market Talk

9 Dec 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

9 Dec 2025, 20:27 UTC

Acquisitions, Mergers, Takeovers

Teck Reports Voting Results From Special Meeting of Hldrs

9 Dec 2025, 20:26 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

9 Dec 2025, 20:21 UTC

Market Talk

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

9 Dec 2025, 19:52 UTC

Earnings

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

9 Dec 2025, 19:17 UTC

Earnings

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

9 Dec 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Dec 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 Dec 2025, 17:11 UTC

Earnings

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Peer Comparison

Price change

Prothena Corp PLC Forecast

Price Target

By TipRanks

93.85% upside

12 Months Forecast

Average 20.8 USD 93.85%

High 36 USD

Low 8 USD

Based on 5 Wall Street analysts offering 12 month price targets forProthena Corp PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Prothena Corp PLC - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 7.35Support & Resistance

All events are bearish.

Sentiment

By Acuity

156 / 374 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Prothena Corp PLC

Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.